Tag: Minimal Residual Disease Management

Home / Minimal Residual Disease Management

Categories

Obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
minimal-residual-disease-management

Scan the code